Sensitivity of liver injury in heterozygous sod2 knockout mice treated with troglitazone or acetaminophen

Toxicologic Pathology

Volumn 37, Issue 2, 2009, Pages 193-200

  Fujimoto, Kazunori ^a,b   Kumagai, Kazuyoshi ^a   Ito, Kazumi ^a   Arakawa, Shingo ^a   Ando, Yosuke ^a   Oda, Sen Ichi ^b   Yamoto, Takashi ^a   Manabe, Sunao ^a  

^a DAIICHI SANKYO CO   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Acetaminophen; Drug induced liver injury; Hepatotoxicity; Mitochondrial toxicity; Sod2+ mice; Troglitazone

Indexed keywords

AMINOTRANSFERASE; MANGANESE SUPEROXIDE DISMUTASE; PARACETAMOL; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE TRIPHOSPHATE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHROMAN DERIVATIVE; LACTATE DEHYDROGENASE; SUPEROXIDE DISMUTASE;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; KNOCKOUT GENE; LIVER INJURY; LIVER NECROSIS; MITOCHONDRIAL TOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BLOOD; CELL CULTURE; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; GENE INACTIVATION; GENETICS; HETEROZYGOTE; INJURY; LIVER; LIVER CELL; LIVER MITOCHONDRION; METABOLISM; METHODOLOGY; MOUSE MUTANT; NECROSIS; PATHOLOGY; SENSITIVITY AND SPECIFICITY; TIME;

ANIMALIA; MUS;

ACETAMINOPHEN; ADENOSINE TRIPHOSPHATE; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CELL SURVIVAL; CELLS, CULTURED; CHROMANS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE KNOCKOUT TECHNIQUES; HEPATOCYTES; HETEROZYGOTE; L-LACTATE DEHYDROGENASE; LIVER; MICE; MICE, KNOCKOUT; MITOCHONDRIA, LIVER; MODELS, ANIMAL; NECROSIS; SENSITIVITY AND SPECIFICITY; SUPEROXIDE DISMUTASE; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 67049169349     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623308329282     Document Type: Article

References (20)

1. Bedoucha, M, E Atzpodien, and UA Boelsterli (2001). Diabetic KKAy mice exhibit increased hepatic PPAR1 gene expression, and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol, 35, 17-23.
2. Boelsterli, UA, and PLK Lim (2007). Mitochondrial abnormalities-A link to idiosyncratic drug hepatotoxicity? Toxicol Appl Pharmacol, 220, 92-107.
3. Bova, MP, D Tam, G McMahon, and MN Mattson (2005). Troglitazone induced a rapid drop of mitochondrial membrane potential in liver HepG2 cells. Toxicol Lett, 155, 41-50.
4. Chen, C, GE Hennig, HE Whiteley, JC Corton, and JE Manautou (2000). Peroxisome proliferator-activated receptor alpha-null mice lack resistance to acetaminophen hepatotoxicity following clofibrate exposure. Toxicol Sci, 57, 338-44.
5. Dykens, JA, and Y Will (2007). The significance of mitochondrial toxicity testing in drug development. Drug Discov Today, 12, 777-85.
6. Herman, JR, LA Dethloff, EJ McGuire, RF Parker, KM Walsh, AW Gough, H Masuda, and FA la Iglesia (2002). Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone. Toxicol Sci, 68, 226-36.
7. James, LP, PR Mayeux, and JA Hinson (2003). Acetaminophen-induced hepatotoxicity. Drug Metab Dispos, 31, 1499-506.
8. Jia, DM, A Tabaru, T Akiyama, S Abe, and M Otsuki (2000). Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol, 15, 1183-91.
9. Kon, K, JS Kim, H Jaeschke, and JJ Lemasters (2004). Mitochondrial permeability transition in acetaminophen-induced necrosis and apoptosis of cultured mouse hepatocytes. Hepatology, 40, 1170-79.
10. Lebovitz, RM, H Zhang, H Vogel, J Cartwright, Jr, L Dionne, N Lu, S Huang, and MM Matzuk (1996). Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci USA, 93, 9782-87.
11. Masubuchi, Y, S Kano, and T Horie (2006). Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology, 222, 233-39.
12. Masubuchi, Y, C Suda, and T Horie (2005). Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J Hepatol, 42, 110-16.
13. McGuire, EJ, LA Dethloff, KM Walsh, FA de la Iglesia, and H Masuda (1997). Subchronic toxicity of the antidiabetic troglitazone in B6C3F1 mice. Toxicologist, 36, 273. Abstract 1388.
14. New, LS, S Saha, MM Ong, UA Boelsterli, and EC Chan (2007). Pharmacokinetic study of intraperitoneally administered troglitazone in mice using ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom, 21, 982-88.
15. Ong, MMK, AS Wang, KY Leow, YM Khoo, and UA Boelsterli (2006). Nimesulide-induced hepatic mitochondrial injury in heterozygous. Sod2+/-mice. Free Radic Biol Med, 40, 420-29.
16. Ong, MMK, CL Latchoumycandane, and UA Boelsterli (2007). Troglitazone-induced hepatic necrosis in an animal model of silent genetics mitochondrial abnormalities. Toxicol Sci, 97, 205-13.
17. Reid, AB, RC Kurten, SS McCullough, RW Brock, and JA Hinson (2005). Mechanisms of acetaminophen-induced hepatotoxicity: role of oxidative stress and mitochondrial permeability transition in freshly isolated mouse hepatocytes. J Pharmacol Exp Ther, 312, 509-16.
18. Tirmenstein, MA, CX Hu, TL Gales, BE Maleeff, PK Narayanan, E Kurali, TK Hart, HC Thomas, and LW Schwartz (2002). Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol Sci, 69, 131-38.
19. Watanabe, T, Y Ohashi, M Yasuda, M Takaoka, T Furukawa, T Yamoto, A Sanbuissho, and S Manabe (1999). Was it not possible to predict liver dysfunction caused by troglitazone during nonclinical safety studies? Reevaluation of Safety. Iyakuhin Kenkyu, 30, 537-46.
20. Watanabe, T, T Furukawa, S Sharyo, Y Ohashi, M Yasuda, M Takaoka, and S Manabe (2000). Effect of troglitazone on the liver of a Gunn rat model of genetic enzyme polymorphism. J Toxicol Sci, 25, 423-31.